- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Thousand Oaks Today
By the People, for the People
Brookstone Capital Management Increases Amgen Stake
Investment firm adds 3,098 shares of biotech giant in Q4
Mar. 31, 2026 at 8:36am
Got story updates? Submit your updates here. ›
Brookstone Capital Management's increased investment in Amgen reflects the firm's confidence in the biotech company's long-term growth potential.Thousand Oaks TodayBrookstone Capital Management, a financial advisory firm, increased its position in Amgen Inc. (NASDAQ: AMGN) by 4.3% in the fourth quarter of 2025, according to a recent SEC filing. The firm now owns 74,409 shares of the medical research company's stock, valued at $24.4 million.
Why it matters
Amgen is one of the world's largest independent biotechnology companies, developing innovative medicines for patients with serious illnesses. Brookstone's increased stake suggests the firm sees long-term growth potential in Amgen's pipeline and business model.
The details
According to the 13F filing, Brookstone Capital Management acquired an additional 3,098 shares of Amgen during the fourth quarter. This builds on the firm's existing position, which now makes up a sizable portion of its overall portfolio. Amgen's stock has seen volatility in recent quarters due to patent expirations and increased competition, but the company remains a leader in the biopharmaceutical industry.
- Brookstone Capital Management filed its 13F report for Q4 2025 on March 31, 2026.
- The firm increased its Amgen stake during the three-month period ending December 31, 2025.
The players
Brookstone Capital Management
A financial advisory firm that manages investments for individual and institutional clients.
Amgen Inc.
A global biotechnology company that discovers, develops, manufactures, and delivers human therapeutics.
The takeaway
Brookstone Capital's increased stake in Amgen suggests the firm sees long-term growth potential in the biotech company, despite recent market volatility. As one of the world's largest independent biotechnology firms, Amgen's performance is closely watched by investors seeking exposure to innovative pharmaceutical developments.
